MAPT and tauopathy: A study indicated that intracerebroventricular administration of infliximab reduced Aβ plaques and tau phosphorylation in APP/PS1 mice [93] and resulted in cognitive improvement in a human case [94], while recent research confirms the protective cerebral effects (reduced microgliosis, neuronal loss, and tau phosphorylation) of TNF-α inhibitors in a transgenic mouse model of tauopathy [114].